Skip to content

The Impact of Low-Dose Esketamine on Postoperative Acute Pain in Patients Undergoing Laparoscopic Radical Gastrectomy for Gastric Cancer: A Prospective, Double-Blind, Randomized Controlled Clinical Trial

The Impact of Low-Dose Esketamine on Postoperative Acute Pain in Patients Undergoing Laparoscopic Radical Gastrectomy for Gastric Cancer: A Prospective, Double-Blind, Randomized Controlled Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101909
Enrollment
Unknown
Registered
2025-05-06
Start date
2025-05-06
Completion date
Unknown
Last updated
2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Control group:The same dose of normal saline is given after endotracheal intubation and intraoperatively. Postoperative analgesic pump sufentanil 4ug/kg (up to 250 ug) diluted to 200ml with normal sal
Experimental group:Endotracheal intubation was followed by esketamine 0.2 mg/kg for 10 minutes, followed by 0.1 mg/kg/hour until the end of surgery. Postoperative analgesic pump sufentanil 4 ug/kg (up

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Expected to undergo laparoscopic radical gastrectomy; 2. Age 18-80 years old; 3. Patients with ASA grade I.-III; 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Difficulty communicating or understanding; 2. There are contraindications to esketamine; 3. Long-term use of opioids or non-steroidal drugs; 4. Refusal to participate in the study.

Design outcomes

Primary

MeasureTime frame
The incidence of moderate to severe pain within 48 hours postoperatively;

Secondary

MeasureTime frame
Adverse reactions;Sleep quality;Quality of postoperative recovery;Postoperative delirium;

Countries

China

Contacts

Public ContactXu Pingbo

Zhejiang Cancer Hospital

xupingboshanghai@163.com+86 18017312996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026